Dishman Carbogen, Client to Invest CHF 25M to Expand Swiss Sites
10 Jun 2025
2 Min Read
CW Team
The Company鈥檚 subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.
The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:
- Aarau site: installation of 850-litre reactors and 0.4 m虏 agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.
- Neuland site: installation of 850-litre reactors and 0.4 m虏 agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
鈥淭his expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,鈥� said Stephan Fritschi, CEO at CARBOGEN AMCIS. 鈥淲e鈥檙e proud to continue building on our strong trust and technical collaboration foundation.鈥�
CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company鈥檚 infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.
鈥淏y investing in both Aarau and Neuland, we鈥檙e ensuring that our infrastructure keeps pace with our customers鈥� ambitions,鈥� said Carl Baker, Vice President Business Unit Drug Substance. 鈥淭hese upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.鈥�
With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.
The Company鈥檚 subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:Aarau site: installation of 850-litre reactors and 0.4 m虏 agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.Neuland site: installation of 850-litre reactors and 0.4 m虏 agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.鈥淭his expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,鈥� said Stephan Fritschi, CEO at CARBOGEN AMCIS. 鈥淲e鈥檙e proud to continue building on our strong trust and technical collaboration foundation.鈥滳ARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company鈥檚 infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.鈥淏y investing in both Aarau and Neuland, we鈥檙e ensuring that our infrastructure keeps pace with our customers鈥� ambitions,鈥� said Carl Baker, Vice President Business Unit Drug Substance. 鈥淭hese upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.鈥漌ith facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.
Next Story
Solarium To Launch Solar Module Unit In Gujarat
Solarium Green Energy Limited, a leading player in India鈥檚 rooftop solar segment, has announced its strategic re-entry into solar module manufacturing. The company plans to set up a fully automated, high-capacity manufacturing facility in Ahmedabad, Gujarat, with an annual output of 1,000 MW. The total estimated capital expenditure for the plant is around Rs 700 million, with additional working capital to be arranged in a 3:1 debt-to-equity ratio.This backward integration initiative is designed to strengthen Solarium鈥檚 control over critical components in its engineering, procurement and co..
Next Story
Inox Wind Energy To Merge With Inox Wind
The INOXGFL Group, a key player in India鈥檚 energy transition sector, announced that the National Company Law Tribunal (NCLT), Chandigarh Bench, has approved the merger of Inox Wind Energy Ltd (IWEL) into Inox Wind Ltd (IWL). The order, dated 10 June 2025, paves the way for streamlining the group鈥檚 wind energy vertical and strengthening the financial and operational base of the consolidated entity.Following the merger, IWL will see a significant improvement in its balance sheet with a reduction in liabilities of approximately Rs 20.5 billion. The amalgamation is also expected to deliver enh..
Next Story
Hilton Develops India-Made Forged Railway Wheelsets
Hilton Metal Forging Ltd has successfully developed and manufactured indigenous Railway Forged Wagon Wheelsets, which have been inspected and approved by RITES, the Indian government鈥檚 quality assurance agency. Each wheelset includes two forged wheels and one forged axle, with every rail coach or wagon requiring four such wheelsets.The company aims to meet the growing demand from Indian railway wagon manufacturers and reduce reliance on Chinese imports. Under the 鈥淢ake in India鈥� initiative, Hilton plans to manufacture over 3,000 wheelsets in FY26 and scale up to more than 12,000 units in..
